Press release BoxID: 651890 (Ypsomed AG)
  • Ypsomed AG
  • Brunnmattstrasse 6
  • 3401 Burgdorf
  • Contact person
  • Benjamin Overney
  • +41 (34) 4244159

Ypsomed Is Expanding to Italy

(PresseBox) (Burgdorf, ) As of the first quarter of 2014 Ypsomed is represented on the Italian market by its own subsidiary. It means that Ypsomed will now also have a presence in the third largest diabetes market in Europe with the unique tubeless insulin pump mylife™ OmniPod®.

With a population of 59 million and a diabetes prevalence rate of around 7.9%, Italy is Europe's third largest diabetes market. National health service expenditure associated with diabetes mellitus is about €10 billion a year. Ypsomed will build up market penetration sequentially, initially focusing on insulin pump therapy with the mylife™ OmnPod®. Pump patients in Italy are supported by over 800 specialised diabetes clinics. Initially the field sales force will concentrate on clinics in certain regions due to regional variations in the Italian healthcare system.

The registered office of Ypsomed Italia srl is located in Varese, Lombardy. The company is led by an Ypsomed manager with over 20 years of experience in diabetes care.

Ypsomed AG

The Ypsomed Group is a leading, independent Swiss developer and manufacturer of injection systems for selfmedication and a renowned diabetes specialist with over 25 years of experience. Founded in 2003 from the wellknown company Disetronic, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements; contract development and manufacturing; as well as the assembly of injection systems with medications, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide.

Ypsomed has its headquarters in Burgdorf and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed group has around 1,000 employees.